Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Spotlight on Saudi Arabia

    August 25, 2015 | Saudi Arabia, emerging markets 

    Published in eyeforpharma 20 May by Rachel Howard

    What are the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom?

    Traditionally the Middle East and North Africa (MENA) region has been overlooked by pharmaceutical companies, with the region contributing only about 2% of global pharmaceutical sales in 2010. Difficult regulatory environments and political turmoil have compounded the perceived lack of attractiveness of the region as a whole.

    As we reach the middle of the decade, could the tide be turning? Over the last year, I have noticed increasing industry interest in Saudi Arabia (KSA) – and with good reason given it is the fastest growing pharmaceutical market in the Middle East, experiencing double-digit growth. In this article, I will take a look at the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom.

    Background

    Though vast swathes of the country are uninhabitable desert, Saudi Arabia has a population fast approaching 30 million. It is a young country, with over half of the population under 30 years of age. As it is home to the holy Islamic cities of Mecca and Medina, its population receives a seasonal boost as over two million pilgrims visit each year to perform the Hajj. It also contains about a quarter of the world’s known petroleum reserves, and oil revenues account for approximately 90 percent of the government’s income.

    A key pillar of Saudi Arabia’s internal stability relative to much of the surrounding region has been the kingdom’s generous social welfare system, of which healthcare forms an important segment. Healthcare services are available free of charge not only to Saudi citizens but also to all pilgrims, regardless of their nationality. Recent decades have seen considerable improvement in both the quantity and quality of healthcare services. A Royal Decree in 2002 resulted in sizeable expansion of the primary care network. Care in the top public hospitals, such as Riyadh’s renowned King Fahad Medical City, easily rivals that of the West, with imported medical technology and state-of-the-art facilities. Medical education is also fully funded by the state, including overseas training. As a result, many physicians are trained in leading US and UK medical schools.

    However, not all is rosy. Despite the country’s affluence and stated commitment to healthcare, indicators suggest Saudi Arabia’s overall healthcare performance remains mediocre compared with the West, with an infant mortality rate that is double the average and a shorter life expectancy.

    Read the full article at http://www.researchpartnership.com/news/2015/05/spotlight-on-saudi-arabia/

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Infographic: Therapy Watch Hyperlipidaemia

    Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

    Article: The rise of the healthcare influencer

    In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

    Personalized Oncology: Calling for a New Kind of Partnership:

    In the 1990s, biomarkers were the future of personalized medicine and a “lab on a chip” was the holy grail of understanding patient health. As much as past predictions of...

    How to elevate your communications testing with AI powered insights and analytics

    Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

    EVOKE STRENGTHENS LEADERSHIP TEAM IN EUROPE TO DELIVER MORE INTEGRATED CLIENT SOLUTIONS

    *Corrina Safeio, promoted to Group Managing Director taking on responsibility for Evoke London and Evoke Mind+Matter *Lee Wales, promoted to Deputy Managing Director at Evoke Mind+Matter UK *Holly Ford, promoted...

    Infographic: Therapy Watch Psoriasis

    Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

    Article: How behavioural economics can help you build better brand communications

    For pharma marketers, accelerating brand performance means maximizing return on investment. Your campaigns need to trigger the right emotions, and the right actions, in your audience.

    Article: From KOLs to KOIs – How to identify and engage the new healthcare influencers

    Paul Reed and Basil Feilding investigate a new breed of KOLs with online influence and explain why pharma needs to join the conversation.

    New syndicated patient reports –

    Living with Uterine Fibroids and Endometriosis US 2022

    Webcast: From perceptions to prescribing: Combining forces with next-generation tracking and benchmarking to accelerate brand performance

    In this webcast we demonstrate RP and STEM's integrated approaches which gives clients the level of insights they need to accelerate brand performance.